Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Regimen shows promise as salvage for classical HL

Publish date:: February 22, 2019

Key clinical point: Brentuximab vedotin plus ifosfamide, gemcitabine, and vinorelbine (BV-IGEV) appears effective as salvage for patients with relapsed/refractory classical Hodgkin lymphoma.

Major finding: Of 28 patients, 27 responded to BV-IGEV.

Study details: A retrospective study of 28 patients.

Disclosures: The authors reported having no conflicts of interest.

Citation:

Abuelgasim KA et al. Bone Marrow Transplant. 2019 Jan 30. doi: 10.1038/s41409-019-0454-z.

This Week's Must Reads

Investigators recommend expanding testing for Lynch syndrome,

High-dose rituximab with autologous-SCT promising for relapsed/refractory DLBCL,

Insurance type, distance traveled did not affect survival in DLBCL patients treated with CAR-T therapy,

National Watchman registry reports impressive procedural safety,

Avadomide monotherapy demonstrated preliminary efficacy in relapsed/refractory DLBCL,

Must Reads in Hodgkin Lymphoma

ECHELON-1 update: A+AVD bests ABVD in Hodgkin lymphoma,

Adult survivors of childhood cancer are experiencing fewer major cardiac events,

Worse PFS when radiation is withheld in early-stage Hodgkin lymphoma,

Cell count ratios appear to predict thromboembolism in lymphoma,

Regimen shows promise as salvage for classical HL,